Virtual Symposium (Expired): Consider the Comorbidities and Clinical Challenges: Individualizing Stroke Prevention Therapy in Complex Patients with NVAF

Through a series of didactic presentations and patient-case discussions, this activity will address the updated 2014 AHA/ACC/HRS guideline recommendations for NVAF, and the safety and efficacy of OACs along with clinical considerations of patients with NVAF and comorbidities associated with metabolic syndrome. Expert faculty will also highlight current and emerging reversal agents for OACs and recent regulations and processes for reimbursement designed to improve post-discharge adherence to anticoagulation/ antithrombotic treatment plans and reduce hospital readmissions.

Current Diagnostic, Risk Stratification and Treatment Guidelines for NVAF

Faculty: Deepak L. Bhatt, MD, MPH

Oral Anticoagulants for Stroke Prevention in NVAF: Optimizing Benefits and Reducing Risks

Faculty: Christian T. Ruff, MD, MPH

Reversal Agents and Procedures for Bleeding Management

Faculty: Christian T. Ruff, MD, MPH

Practical Clinical Management of NVAF

Faculty: Elaine M. Hylek, MD, MPH

Audience Q&A and Closing Remarks

Presenter: All Faculty